Restoration of the Expression of Transports Associated with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity  by Tao, Juan et al.
Restoration of the Expression of Transports
Associated with Antigen Processing in Human
Malignant Melanoma Increases Tumor-Specific
Immunity
Juan Tao1,3, Yan Li1,3, Ye-Qiang Liu1,3, Lin Wang1, Jing Yang1, Jing Dong1, Yan Wu1, Guan-Xin Shen2
and Ya-Ting Tu1
The transporter associated with antigen processing (TAP) is essential for peptide delivery from the cytosol into
the lumen of the endoplasmic reticulum (ER), where these peptides are loaded on HLA I molecules. Our
previous study found that expressions of TAP were reduced in human malignant melanoma (MM) lesions and
associated with histopathologic characteristics. In this study, we further investigate expressions of TAP and HLA
class I antigen in three human MM cell lines. pEGFP-TAP1/TAP2/TAP1þ TAP2 were used to restore the
expressions of TAP in the antigen presentation pathway-deficient MM cell line A375. TAP1- and TAP1þ TAP2-
transfected A375 increased TAP1, TAP2, and HLA class I antigen expression and antigen presentation. TAP1- and
TAP1þ TAP2-transfected A375 exhibited a dramatic increase in Melan-A-specific cytotoxic T lymphocytes (CTLs)
compared with TAP2-transfected A375 or empty vector. These CTLs were capable of killing TAP1- and
TAP1þ TAP2-transfected A375. TAP1þ TAP2-transfected A375 generated the highest frequency of Melan-
A-specific IL-12 and interferon (IFN)-g-producing CD8þ T cells compared with TAP1, TAP2, and empty vector.
Therefore, TAP expression restores both antigen presentation and immunogenicity in A375 melanoma cells and
concomitantly increases IL-12 and IFN-g production in tumor antigen-specific CTLs; TAP should be considered
as a part of the immunotherapies for MM.
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INTRODUCTION
The transporter associated with antigen processing (TAP) is a
key factor in the HLA class I antigen presentation pathway.
TAP translocates peptides derived mainly from proteasomal
degradation from the cytosol into the lumen of the
endoplasmic reticulum (ER), where these peptides are loaded
onto HLA class I molecules. Peptides–HLA class I complex
is transported to the cell surface to present the antigen to
the cytotoxic T lymphocytes (CTL). In case of malignant
transformation or viral infection of the cells, an additional
set of peptides is presented to CTL, leading to an efficient
elimination of the infected or malignant cells. TAP is a
heterodimeric transmembrane protein that comprises the
homologous subunits TAP1 and TAP2 (Kelly et al., 1992).
Both subunits are essential and sufficient for peptide
transport (Powis et al., 1991; Spies and DeMars, 1991;
Meyer et al., 1994).
In many cancers, including malignant melanoma (MM),
immune escape has been associated with ineffective antigen
processing and presentation of tumor-specific peptides
because of low to nondetectable levels of TAP1 and/or
TAP2 (Kageshita et al., 1999; Kamarashev et al., 2001;
Cresswell et al., 2001). Accordingly, suppression or loss of
TAP function in tumors generally results in failure of
recognition and elimination by epitope-specific effector CTLs
(Chen et al., 1996; Alimonti et al., 2000; Evans et al., 2001).
Recently, it was observed that restoration of TAP1 expression
by transfection resurrects the processing and presentation of
viral antigens and the melanoma-associated antigen. Immu-
nization with B16F10 (murine MM cell line)/rTAP1-trans-
fected cells generates CTLs that are capable of killing
B16F10/rTAP1-transfected targets and B16F10 targets defi-
cient in TAP1 (Zhang et al., 2003). However, it is still unclear
whether the reduction of TAP1 and/or TAP2 resulting in the
deficiency of HLA class I expression exists in human MM cell
lines and whether the restoration of TAP expression in human
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MM cell lines enhances MM immune response. Therefore, in
our study, we investigate the expression of TAP1 and TAP2 in
human MM cell lines, compare their expression difference
in MM cell line, A375 cells transfected with TAP1, TAP2, and
TAP1þTAP2 DNA, and examine the effect of the restoration
of TAP1 and TAP2 expression on HLA class I antigen
surface expression in A375 cells and function of tumor
antigen-specific CTLs.
RESULTS
Downregulation of TAP1 and TAP2 in human melanoma cell
lines
To verify the hypothesis that TAP contributes to deficiency of
HLA class I expression exhibited by human MM cell lines,
mRNA and protein expression analyses were performed. As
shown in Figure 1a, reverse transcription-PCR analysis revealed
that the expression levels of both TAP1 and TAP2 were much
more reduced in human MM cell lines when compared to the
positive control, melanocytes. Only traces of TAP1 and TAP2
could be detected in the MM cell line A375. As shown in
Figure 1b, the reduction of TAP1 and TAP2 protein was
demonstrated in three MM cell lines examined by western
blotting, and HLA class I expression was reduced along with
the decrease of TAP1 and TAP2 in the MM cell lines, especially
A375 cells, the least expressions of TAP and HLA class I among
MM cell lines examined by FACS in Figure 1c.
Confocal fluorescent microscopic examination reveals that the
translated TAP protein is located in the endoplasmic reticulum
For the visualization of the TAP protein, the EGFP gene was
introduced at the N terminus of TAP1 and TAP2 in a plasmid
construct to be translated as a fusion protein, EGFP-TAP1 and
EGFP-TAP2. Each plasmid together with an ER marker
(pDsRed2-ER vector) was transiently transfected into A375
cells, and the localizations of the expressed proteins were
analyzed by confocal microscopy. A375 cells transfected
with pDsRed2-ER vector showed ER distribution for the red
fluorescence (Figure 2b and e), and cells transfected with the
EGFP-TAP showed the green fluorescence (Figure 2a and d).
The localizations of EGFP-TAP1 and EGFP-TAP2 overlapped
with that of the ER marker, indicating that TAP protein
localized subcellularly into the ER (Figure 2c and f).
A375 cells transfected with TAP upregulate TAP1, TAP2,
and HLA class antigen I surface expression
TAP1 and TAP2 protein expressions were examined in A375
cells transfected with TAP1, TAP2, and TAP1þ TAP2 by
western blot. TAP1 and TAP2 protein levels in A375
transfected TAP1 and TAP1þTAP2 were increased com-
pared to the negative control group. TAP1 protein expression
in A375 transfected with TAP1 had no significant difference
in A375 transfected with TAP1þ TAP2 (Figure 3a). TAP2
protein levels in A375 transfected TAP1, TAP2, and
TAP1þ TAP2 were increased compared to the negative
control group. However, TAP1 protein expression in A375
transfected with TAP2 was not increased, and TAP2 protein
expression in A375 transfected with TAP2 was less in A375
transfected with TAP1þ TAP2 (Figure 3a). Then the effect of
TAP expression on cell surface HLA class I antigen expression
in TAP-transfected A375 cells was investigated. HLA class I
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Figure 1. Deficiency of surface HLA class I expression in melanoma cell lines was due to the TAP1 and TAP2 downregulation. (a) Expressions of TAP1
and TAP2 mRNA in three melanoma cell lines, A375, A875, and KZ28, and control melanocytes, using RT-PCR. (b) Expressions of TAP1 and TAP2 protein
in three melanoma cell lines, A375, A875, and KZ28, and control melanocytes, using western blot. (c) Expressions of HLA class I antigen in three
melanoma cell lines, A375, A875, KZ28, and control melanocytes, using flow cytometry.
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Figure 2. Intracellular expression and localization of transfected TAP
protein confocal fluorescent microscopy to demonstrate the expression and
distribution of TAP proteins. A375 cells were transfected with pDsRed2-ER
(b, e), pEGFP-TAP1 (a), pEGFP-TAP2 (d), pEGFP-TAP1þ pDsRed2-ER (c), and
pEGFP-TAP2þpDsRed2-ER (f). (b) For the detection of endogenous
calreticulin protein, red fluorescence was observed. (a) For the detection of
EGFP protein, green fluorescence was noted. (c) Colocalization of EGFP and
calreticulin was demonstrated by the yellow color in the combined image.
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surface expression on A375 cells was compared to surface
expression on A375/TAP1, A375/TAP2, and A375/
TAP1þ TAP2 cells, using FACS analysis. A375/TAP1, A375/
TAP2, and A375/TAP1þ TAP2 cells exhibited significant
expression of HLA class antigen I on the cell surface (Figure
3c). This was in contrast to A375 cells, which had only a small
amount of HLA class antigen I. TAP1þ TAP2-transfected A375
cells express the highest level of HLA class antigen I in the
experimental groups. TAP1-transfected A375 cells express it
higher than do the TAP2-transfected A375 cells.
TAP expression restores antigen presentation and
immunogenicity in A375 cells
Peripheral blood mononuclear cells (PBMCs) from HLA-
A*0201 donors were stimulated three times with a melanoma
cell line loaded with Melan-A peptide analog (ELAGIGILTV).
We performed a CTL assay using A375 cells transfected with
the various DNA constructs (TAP1, TAP2, and TAP1þTAP2)
as target cells and Melan-A-specific-CTL as effector cells. As
shown in Figure 4, A375 cells transfected with TAP1 and
TAP1þTAP2 generated significantly higher percentages of
specific lysis at the 9:1 (19.3±0.7%, 25.5±2.1% vs
9.73±0.8%, Po0.001) and 27:1 (48.3±4.7%, 57.1±6.5%
vs 16.4±3.5%, Po0.001) effector/target (E/T) ratios com-
pared with A375 cells transfected with TAP2. Although A375
cells transfected with TAP1þ TAP2 generated higher percen-
tages of specific lysis than A375 cells transfected with TAP1,
there was no significant difference between them (P40.05).
Our results suggested that A375 cells transfected with TAP1
and TAP1þTAP2 were capable of directly presenting antigen
through the HLA class I pathway to CTL cells more efficiently
than A375 cells transfected with TAP2.
TAP expression increases Melan-A-specific IFN-c and
IL-12-producing CTL
Melan-A-specific CD8þ T cell lines were highly lytic against
A375 cell lines transfected with TAP1/TAP1þTAP2 and they
efficiently produced IFN upon stimulation with these cells, as
illustrated by the high fraction of IFN-g/CD8 double-positive
cells (Figure 5). A strong correlation was found between the
percentage of IFN-g/CD8 double-positive cells and the
percentage of lysis (Figure 5a). There was a similar approach
between the percentage of IL-12-positive cells and the
percentage of lysis (Figure 5b). A positive correlation was
also found between the percentage of IFN-g-positive cells
and the percentage of IL-12-positive cells (Figure 5c). These
results indicated that TAP expression in A375 cells induced a
Th1-type tumor-specific immune response.
DISCUSSION
Our results showed that the expressions of TAP1 and TAP2 in
three human MM cell lines were downregulated compared to
the positive control, melanocytes, and the expressions of
TAP1 and TAP2 in the human MM cell line A375 cells were
the lowest among them. The view that TAP has an important
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Figure 3. The transfection of A375 cells with TAP induces HLA class I antigen surface expression. (a) TAP1 and TAP2 expression was detected by western
blot: lane 1, A375 cells; lane 2, TAP1þTAP2-transfected A375 cells; lane 3, TAP1-transfected A375 cells; and lane 4, TAP2-transfected A375 cells.
(b) Surface HLA class I antigen expression is detected by flow cytometry.
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Figure 4. CTL assays to demonstrate enhanced antigen presentation
through the HLA class I pathway in A375 cells transfected with TAP. CTL
assays with various E/T ratios (E/T¼ 1:1, 3:1, 9:1, 27:1) were performed as
described in Materials and Methods. A375 cells transfected with various
DNA constructs (TAP1, TAP2, and TAP1þ TAP2) were used as target cells,
whereas Melan-A-specific CD8þ T cells were used as effector cells.
*Po0.01, **Po0.01.
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function in class I assembly derives from the observation that
it not only delivers peptides to the ER, but also it is involved
in the formation of a large loading complex critical for class I
maturation (Powis et al., 1991; Spies and DeMars, 1991;
Meyer et al., 1994). Therefore, we examined the expression
of HLA class I and found that its expression was reduced
compared to melanocytes as well as TAP in human MM cell
lines, especially A375 cells. These indicated that the
deficiencies of HLA class I caused by the reduction of TAP
in the antigen presentation pathway existed in human MM
cell lines, especially A375 cells. These results are in line with
the murine MM cell line B16F10, which is deficienct in
components of the MHC class I antigen-processing pathway,
including TAP, MHC class I antigen surface expression
(Zhang et al., 2007). However, TAP expression has been
associated with tumor-infiltrating lymphocytes, a character-
istic of good clinical outcome (Zhang et al., 2003, Dissemond
et al., 2003) and spontaneous regression of MM (Panago-
poulos and Murray, 1983). Therefore, we transfected TAP1,
TAP2, and TAP1þTAP2 DNA into A375 cells, which had the
lowest levels of TAP1 and TAP2, and evaluated their effect on
tumor immune reaction.
To determine whether the EGFP-N1 vector affected the
subcellular localization of TAP, we linked the EGFP gene to
the TAP1 gene or the TAP2 gene. Transfection and
subsequent examination with a confocal fluorescent micro-
scope revealed that A375 cells transfected with TAP/EGFP
and pDsRed2-ER vector (an ER marker) showed ER localiza-
tion of TAP by yellow color in the combined image (Figure
2c). We further detected the protein expression of TAP1 and
TAP2 in A375 cells stably transfected with TAP1, TAP2,
and TAP1þ TAP2 DNA. Our results showed that not only
the expressions of TAP1 but also the expressions of TAP2
were increased in A375 cells transfected with TAP1 DNA.
The TAP1 protein expression in A375 transfected with TAP1
had no significant difference in A375 transfected with
TAP1þTAP2. However, only the expression of TAP2, not
TAP1, was increased in A375 cells transfected with TAP2
DNA, and TAP2 protein expression in A375 transfected
with TAP2 was less in A375 transfected with TAP1þTAP2. In
A375 cells, TAP1 expression increased the expression of
TAP2, but not vice versa. Our results are in line with the
observation that the expression level of TAP1 determines the
number of functional heterodimeric TAP molecules in the ER
(Zhu et al., 1999; Herzer et al., 2003). The role of TAP1 as an
assembly platform for newly synthesized unstable TAP2
would explain these puzzling and so far poorly understood
observations (Keusekotten et al., 2006). We examined HLA
class I surface expression on A375 cells transfected with
TAP1, TAP2, and TAP1þTAP2 DNA and found that
TAP1þ TAP2-transfected A375 cells expressed the highest
level of HLA class I antigen in the experimental groups and
that TAP1-transfected A375 cells expressed it higher than
TAP2-transfected A375 cells. This indicates that the re-
expression of TAP1 may stabilize the expression of TAP2 and
thus increase the amount of antigenic peptide available for
assembly onto HLA class I molecules in the ER.
In the case of A375 cells, TAP1 and TAP1þTAP2 gene
transfer were able to resurrect the presentation of Melan-A
peptide analog on HLA-A*0201 antigens to allow for Melan-
A-specific CTL killing. A375 cells transfected with TAP1
and TAP1þTAP2 DNA generated significantly higher
percentages of specific lysis compared to the negative
control and A375 cells transfected with TAP2 DNA.
Vaccination by irradiated A375 cells expressing TAP1 and
TAP2 greatly enhances CTL activity toward A375/TAP1 and
A375/TAP1þTAP2 target cells. We observed that the
percentage of IFN-g/IL-12-positive cells were increased in
TAP1 and TAP1þTAP2 groups. IFN-g (Fathallah-Shaykh
et al., 2000) and IL-12 (Coughlin et al., 1998; Duda et al.,
2000) are examples of various other compounds that have
been shown to exert an antitumor effect. We also observed
that there was a strong correlation between the percentage
of IFN-g/IL-12-positive cells and the percentage of lysis.
This indicated that IFN-g and IL-12 might take part in CTL’s
killing of MM.
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Figure 5. Immunization with A375 cells transfected with TAP increased Melan-A specific IFN-c and IL-12-secreting CTL. (a) Correlation between lysis and
IFN-g production by Melan-A-specific CTL in response to an HLA-A*0201 Melan-A-positive melanoma cell line. (b) Correlation between lysis and IL-12
production by Melan-A-specific CTL in response to an HLA-A*0201 Melan-A-positive melanoma cell line. For the lysis experiment, effector and target cells
were incubated at a 27:1 ratio. For IFN-g production, effector and target cells were incubated at a 1:2 ratio in the presence of Brefeldin A before being
fixed, permeabilized with saponin, stained with anti-IFN-g antibody, and analyzed on a FACScan. (c) Correlation between IFN-g and IL-12 production by
Melan-A-specific CTL in response to an HLA-A*0201 Melan-A-positive melanoma cell line.
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In summary, our results indicated that the deficiencies of
HLA class I caused by reduction of TAP in the antigen
presentation pathway existed in human MM cell lines,
especially A375 cells. The re-expression of TAP1 might
stabilize TAP2 in A375 cells, and the restoration of TAP has
the potential to enhance antigen presentation and tumor-
specific immunity.
Materials and methods
Cell lines
The human MM cell lines A375, A875, and KZ28 were
cultured in plastic flasks in DMEM (Gibco, Grand Island, NY)
containing 10% heat-inactivated fetal calf serum (Gibco),
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
(15mM), L-glutamine (2mM), penicillin (100 IUml1), and
streptomycin (100mgml1). Normal human epidermal mela-
nocytes were isolated from neonatal foreskins. Subcutaneous
fat was removed with dissecting scissors and the remaining
tissue was cut into small pieces and incubated with trypsin
(Invitrogen, San Diego, CA) overnight at 4 1C. The epidermal
cells were inoculated in 12-well plates in melanocyte growth
medium and maintained at 37 1C with 5% CO2. Cultures were
provided with fresh medium three times weekly and melano-
cytes were used at passages 3–4 for RNA and protein
extraction. The institutional approval is not necessary.
Reverse Transcription-PCR and gel electrophoresis. Total
RNA from frozen sections was extracted using the TRIzol
reagent (Invitrogen) and was reverse-transcribed and synthe-
sized to complementary DNA using reverse transcriptase
(Promega, Madison, WI). Primers were as follows:
TAP1: 50-TCTCCTCTCTTGGGGAGATG-30 (sense primer)
50-GAGACATGATGTTACCTGTCTG-30 (antisense primer)
TAP2: 50-CTCCTCGTTGCCGCCTTCT-30 (sense primer)
50-TCAGCTCCCCTGTCTTAGTC-30(antisense primer)
b-Actin: 50-AAGAGAGGCATCCTCACCCT-30 (sense primer)
50-TACATGGCTGGGGTGTTGAA-30 (antisense primer)
TAP1, TAP2, and b-actin fragment sizes were 280, 300,
and 218bp, respectively. Band intensities were quantitated
by image analysis system (LEICA Q550I W, Bensheim,
Germany), integral absorbency (IA) of PCR products was
calculated, and IA¼ average absorbency area.
Plasmids construction
Human TAP1 and TAP2 were amplified by PCR from a PBMC
complementary DNA library and subcloned into EGFP-based
mammalian expression vectors (Clontech, Palo Alto, CA). For
deletion mutant constructs, DNA sequences corresponding to
different regions of TAP were amplified by PCR from the
above-mentioned constructs and subcloned into the expres-
sion vectors. All constructs generated from PCR products
were sequenced.
Transfection and confocal microscopy
A total of 2.5 l05 A375 cells were seeded in 12-well plates
and transfected with 10 ng of pDsRed2-ER vector (Clontech),
which is designed for fluorescent labeling of the endoplasmic
reticulum in living cells, and 30 ng of the indicated TAP1 or
TAP2 construct by Lipofectamine 2000 (Invitrogen). Twenty-
four hours after transfection, the cells were removed from the
plates with phosphate-buffered saline, and live cells were
sandwiched between coverslips and glass slides and visua-
lized for fluorescence using the appropriate lasers and filters
to visualize EGFP and DsRed. Confocal images were
acquired with a Laser Scanning Microscope FV500 (Olym-
pus) confocal system and then processed using Adobe
Photoshop (Adobe Systems, San Jose, CA).
Transfection and isolation of TAP stable transfectant clones
A375 cells were transfected with pEGFP-TAP1/TAP2/
TAP1þ TAP2 or empty an vector by Lipofectamine 2000.
After 48 hours, the cells were selected with 400 mgml1
G418 (Invitrogen) for 2 weeks as a selective marker and the
surviving colonies were cloned. The transfectants were
maintained in DMEM containing 10% heat-inactivated fetal
bovine serum, and 150 mg of G418/ml1 at 37 1C in a
humidified atmosphere of 5% CO2.
Western blot
Protein concentrations were determined by BCA Protein
Assay Kit (Pierce, Rockford, IL) and 20 mg equal amounts
of protein was loaded into a 15% polyacrylamide gel.
Proteins were resolved and transferred to a nitrocellulose
membrane using semi-dry transfer (Bio-Rad, Hercules, CA).
After incubating the membranes in a blocking buffer, the
membranes were incubated with TAP1, TAP2, and GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) polyclonal
antibodies (all from Santa Cruz Biotechnology, Santa Cruz,
CA). Immunoreactive bands were visualized by chemilumi-
nescence using a horseradish peroxidase-conjugated IgG
antibodies and ECL kit (Pierce) according to the instructions
of the manufacturer. Quantitative analysis of the blots was
performed with an imaging densitometer.
Generation of Melan-A-specific effector CTL clones from PBMC
To generate HLA-A*0201 antigen-restricted Melan-A-specific
CTLs, Melan-A analog peptide (ELAGIGILTV) was synthe-
sized by Peptide Technologies (Invitrogen) to a purity more
than 99% by HPLC and amino-acid analysis.
Loading with Melan-A analog peptide (ELAGIGILTV) was
performed by incubating stimulator cells with the peptide at
37 1C in a serum-free medium for 2 hours. Stimulator cells
were washed twice to eliminate unbound peptide. Total
PBMCs from HLA-A*0201 donors were isolated using the
Ficoll–Hypaque density–gradient method and then stimulated
in 96-well culture plates with 2104 irradiated stimulator
cells (10,000 rads) in DMEM containing 8% human serum
supplemented with 5 ngml1 IL-6 (Peprotech, London, UK)
during the first stimulation and 10Uml1 IL-2 (Peprotech)
during the second and third stimulations at 7-day intervals.
Cytotoxicity assay for Melan-A-specific effector CTLs using
transfected TAP A375 cells as target cells
CTL assays were performed by quantitative measurements of
lactate dehydrogenase using CytoTox96 nonradioactive
cytotoxicity assay kits (CytoTox96; Promega). Target cells
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suspended in 50 ml DMEM supplemented with 3% fetal calf
serum were placed on a 96-well plate, and effector cells
(stimulated PBMC) suspended in the same medium were also
added to the wells at various E/T ratios in a final volume of
200ml. Untransfected A375 cells were used as a negative
control. After incubation for 4 hours at 371C with 5% CO2,
50 ml supernatant from each well was transferred to an
enzymatic assay plate. Then 50 ml substrate mixture was
added to each well of the enzymatic assay plate, followed by
30minutes of incubation at room temperature. Finally, 30 ml
stop solution was added and the absorbance was recorded at
490 nm. The percentage of specific lactate dehydrogenase
release was calculated by the following equation:
% cytotoxicity ¼ 100½ðA BÞ=ðC DÞ; where A is the
reading of experimental effector signal value, B is the effector
spontaneous background signal value, C is maximum signal
value from target cells, and D is the target spontaneous
background signal value.
FACS assays
Surface expression of the HLA class I antigen was detected by
indirect immunofluorescence. PE-conjugated rabbit anti-
mouse IgG (Dako, Glostrup, Denmark) was used as the
secondary antibody. The mean logarithmic fluorescence
intensity was measured by a FACScan analyzer (Becton
Dickinson, Mountain View, CA).
The production of IFN-g and IL-12 by Melan-A-specific CTL
clones, in response to target cells, was assessed by intracellular
cytokine labeling using a method described by Jung et al.
(Herzer et al., 2003). PE-cy5-conjugated anti-CD8, APC-
conjugated anti-IL-12, and APC-conjugated anti-IFN-g purified
antibodies were purchased from BD Bioscience Pharmingen,
San Diego, CA. T-cell clones were stimulated by Ag-expressing
melanoma cells at the 1:2 ratio in DMEM 10% fetal calf serum
in the presence of Brefeldin A (10mgml1; Sigma-Aldrich, St
Louis, MO). After 6 hours, the cells were fixed for 10minutes at
room temperature in a solution of phosphate-buffered saline
4% paraformaldehyde. After staining with anti-cytokine mAbs,
the cells were resuspended in phosphate-buffered saline and
5,000 events were analyzed on a FACScan.
Statistical analysis
Statistical comparisons of mean values were performed using
one-way analysis of variance, and statistical comparisons of
correlations were performed using Bivariate correlations
analysis. All P-values were determined from two-sided tests.
A significance criterion of Po0.05 was used. In the figures,
P-values are indicated by asterisks (*): Po0.05, Po0.01. The
statistical analysis was performed using SPSS 10.0 software
(SPSS, Chicago, IL).
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